全球基因組編輯市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

全球基因組編輯市場需求預計將從 2023 年的 83.6 億美元達到近 354.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 17.42%。

基因組編輯是指一套先進的生物技術，可以精確修改生物體的遺傳物質。透過利用 CRISPR-Cas9 等方法，研究人員可以瞄準並改變特定的 DNA 序列，促進基因突變的糾正、所需性狀的增強或基因功能的研究。這項技術在醫學、農業和研究等各個領域具有變革潛力，可以進行量身定做的基因干預措施，以改善健康狀況、提高作物產量並增進科學認知。

市場動態

CRISPR 和其他編輯技術的進步為基因操作提供了更精確和更容易的方法，促進了市場擴張。基因組編輯在生物醫學研究中發揮關鍵作用，有助於了解疾病機制、藥物發現和潛在療法，並推動其在生物製藥領域的需求。遺傳性疾病的盛行率日益增加，推動了針對基因突變的療法的開發，進一步推動了市場的發展。在農業和畜牧業中，這種編輯用於增強性狀、提高產量和開發抗病品種，從而促進農業生物技術的發展。支持性的監管框架、增加的研發投資以及基因組編輯在治療各種疾病方面的治療潛力推動了市場的擴張。機構和產業參與者之間的合作推動創新，帶來新穎的應用和療法。儘管面臨脫靶效應和倫理問題等挑戰，但在技術進步及其徹底改變不同領域的生物醫學研究、農業和治療干預的潛力的推動下，基因組編輯市場仍在不斷擴大。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球基因組編輯市場的各個細分市場進行了包容性評估。基因組編輯產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

基因組編輯市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

依技術

• CRISPR-Cas9
• TALEN/MegaTAL
• ZFN
• 大範圍核酸酶
• 其他

按交貨方式

• 離體
• 體內

按申請

• 基因工程（細胞株工程、動物基因工程、植物性因工程等）
• 臨床應用（診斷、治療發展）

按模式

• 合約
• 內部

按最終用途

• 生物技術和製藥公司
• 學術和政府研究機構
• 合約研究組織

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲基因組編輯市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。基因組編輯市場的主要參與者包括Merck KGaA、Cibus Inc.、Recombinetics、Sangamo Therapeutics、Editas Medicine、Precision BioSciences、Crispr Therapeutics、Intellia Therapeutics Inc.、Cari Biosciences Inc.、Cellectis SA、Aetley、Takara Inc. 、Horizo​​​​n Discovery Ltd. (Revvity Inc.)、丹納赫公司、Transposagen Biopharmaceuticals Inc.、Genscript Biotech Corp.、New England Biolabs。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：基因組編輯 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按技術分類的市場吸引力分析
  • 以交付方式分析市場吸引力
  • 市場吸引力分析：依應用分類
  • 按模式分類的市場吸引力分析
  • 按最終用途分類的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球基因組編輯市場分析：依技術分類

• 依技術概述
• 按技術進行歷史和預測數據分析
• CRISPR-Cas9
• TALEN/MegaTAL
• ZFN
• 大範圍核酸酶
• 其他

第 6 章：全球基因組編輯市場分析：以交付方式

• 按交付方式概述
• 按交付方式進行歷史和預測資料分析
• 離體
• 體內

第 7 章：全球基因組編輯市場分析：依應用分類

• 概述：按應用
• 歷史與預測資料分析：按應用分類
• 基因工程（細胞株工程、動物基因工程、植物性因工程等）
• 臨床應用（診斷、治療發展）

第 8 章：全球基因組編輯市場分析：按模式

• 按模式概述
• 按模式進行歷史和預測資料分析
• 合約
• 內部

第 9 章：全球基因組編輯市場分析：依最終用途分類

• 按最終用途分類的概述
• 按最終用途分類的歷史和預測資料分析
• 生物技術和製藥公司
• 學術和政府研究機構
• 合約研究組織

第 10 章：全球基因組編輯市場分析：依地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區按國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲按國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 11 章：基因組編輯公司的競爭格局

• 基因組編輯市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 12 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Merck KGaA
• 公司概況
• 公司收入
• 產品
• 最新動態
• Cibus Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Recombinetics
• 公司概況
• 公司收入
• 產品
• 最新動態
• Sangamo Therapeutics
• 公司概況
• 公司收入
• 產品
• 最新動態
• Editas Medicine
• 公司概況
• 公司收入
• 產品
• 最新動態
• Precision BioSciences
• 公司概況
• 公司收入
• 產品
• 最新動態
• Crispr Therapeutics
• 公司概況
• 公司收入
• 產品
• 最新動態
• Intellia Therapeutics Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Caribou Biosciences Inc
• 公司概況
• 公司收入
• 產品
• 最新動態
• Cellectis SA
• 公司概況
• 公司收入
• 產品
• 最新動態
• AstraZeneca
• 公司概況
• 公司收入
• 產品
• 最新動態
• Takara Bio Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Horizon Discovery Ltd. (Revvity Inc.)
• 公司概況
• 公司收入
• 產品
• 最新動態
• Danaher Corporation
• 公司概況
• 公司收入
• 產品
• 最新動態
• Transposagen Biopharmaceuticals Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Genscript Biotech Corp
• 公司概況
• 公司收入
• 產品
• 最新動態
• New England Biolabs
• 公司概況
• 公司收入
• 產品
• 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

The global demand for Genome Editing Market is presumed to reach the market size of nearly USD 35.49 Billion by 2032 from USD 8.36 Billion in 2023 with a CAGR of 17.42% under the study period 2024-2032.

Genome editing refers to a suite of advanced biotechnological techniques that enable precise modification of an organism's genetic material. By utilizing methods such as CRISPR-Cas9, researchers can target and alter specific DNA sequences, facilitating the correction of genetic mutations, enhancement of desirable traits, or investigation of gene function. This technology holds transformative potential across various fields, including medicine, agriculture, and research, allowing for tailored genetic interventions to improve health outcomes, increase crop yields, and advance scientific understanding.

MARKET DYNAMICS

Advancements in CRISPR and other editing technologies offer more precise and accessible methods for genetic manipulation, fostering market expansion. Genome editing plays a pivotal role in biomedical research, aiding in understanding disease mechanisms, drug discovery, and potential therapies, driving its demand in the biopharmaceutical sector. The increasing prevalence of genetic disorders fuels the development of therapies targeting genetic mutations, further propelling the market. In agriculture and livestock, this editing is used to enhance traits, improve yields, and develop disease-resistant varieties, contributing to its growth in agricultural biotechnology. Supportive regulatory frameworks, increased R&D investments, and the therapeutic potential of genome editing in treating various conditions fuel market expansion. Collaborations among institutions and industry players drive innovation, leading to novel applications and therapies. Despite challenges like off-target effects and ethical concerns, the genome editing market continues to expand, driven by technological advancements and its potential to revolutionize biomedical research, agriculture, and therapeutic interventions across diverse sectors.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genome Editing. The growth and trends of Genome Editing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genome Editing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

• CRISPR-Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
• Clinical Applications (Diagnostics, Therapy Development)

By Mode

• Contract
• In-House

By End-use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genome Editing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genome Editing market include Merck KGaA, Cibus Inc., Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision BioSciences, Crispr Therapeutics, Intellia Therapeutics Inc., Caribou Biosciences Inc, Cellectis S.A., AstraZeneca, Takara Bio Inc., Horizon Discovery Ltd. (Revvity Inc.), Danaher Corporation, Transposagen Biopharmaceuticals Inc., Genscript Biotech Corp, New England Biolabs. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. GENOME EDITING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Technology
  • 3.7.2 Market Attractiveness Analysis By Delivery Method
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Mode
  • 3.7.5 Market Attractiveness Analysis By End-use
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENOME EDITING MARKET ANALYSIS BY TECHNOLOGY

• 5.1. Overview By Technology
• 5.2. Historical and Forecast Data Analysis By Technology
• 5.3. CRISPR-Cas9 Historic and Forecast Sales By Regions
• 5.4. TALENs/MegaTALs Historic and Forecast Sales By Regions
• 5.5. ZFN Historic and Forecast Sales By Regions
• 5.6. Meganuclease Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL GENOME EDITING MARKET ANALYSIS BY DELIVERY METHOD

• 6.1. Overview By Delivery Method
• 6.2. Historical and Forecast Data Analysis By Delivery Method
• 6.3. Ex-vivo Historic and Forecast Sales By Regions
• 6.4. In-vivo Historic and Forecast Sales By Regions

7. GLOBAL GENOME EDITING MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Historic and Forecast Sales By Regions
• 7.4. Clinical Applications (Diagnostics, Therapy Development) Historic and Forecast Sales By Regions

8. GLOBAL GENOME EDITING MARKET ANALYSIS BY MODE

• 8.1. Overview By Mode
• 8.2. Historical and Forecast Data Analysis By Mode
• 8.3. Contract Historic and Forecast Sales By Regions
• 8.4. In-House Historic and Forecast Sales By Regions

9. GLOBAL GENOME EDITING MARKET ANALYSIS BY END-USE

• 9.1. Overview By End-use
• 9.2. Historical and Forecast Data Analysis By End-use
• 9.3. Biotechnology and Pharmaceutical Companies Historic and Forecast Sales By Regions
• 9.4. Academic and Government Research Institutes Historic and Forecast Sales By Regions
• 9.5. Contract Research Organizations Historic and Forecast Sales By Regions

10. GLOBAL GENOME EDITING MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE GENOME EDITING COMPANIES

• 11.1. Genome Editing Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF GENOME EDITING INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Merck KGaA
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Cibus Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Recombinetics
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. Sangamo Therapeutics
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Editas Medicine
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Precision BioSciences
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Crispr Therapeutics
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. Intellia Therapeutics Inc.
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. Caribou Biosciences Inc
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Cellectis S.A.
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. AstraZeneca
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments
• 12.14. Takara Bio Inc.
  • 12.14.1 Company Overview
  • 12.14.2 Company Revenue
  • 12.14.3 Products
  • 12.14.4 Recent Developments
• 12.15. Horizon Discovery Ltd. (Revvity Inc.)
  • 12.15.1 Company Overview
  • 12.15.2 Company Revenue
  • 12.15.3 Products
  • 12.15.4 Recent Developments
• 12.16. Danaher Corporation
  • 12.16.1 Company Overview
  • 12.16.2 Company Revenue
  • 12.16.3 Products
  • 12.16.4 Recent Developments
• 12.17. Transposagen Biopharmaceuticals Inc.
  • 12.17.1 Company Overview
  • 12.17.2 Company Revenue
  • 12.17.3 Products
  • 12.17.4 Recent Developments
• 12.18. Genscript Biotech Corp
  • 12.18.1 Company Overview
  • 12.18.2 Company Revenue
  • 12.18.3 Products
  • 12.18.4 Recent Developments
• 12.19. New England Biolabs
  • 12.19.1 Company Overview
  • 12.19.2 Company Revenue
  • 12.19.3 Products
  • 12.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Technology (USD MN)
• CRISPR-Cas9 Market Sales By Geography (USD MN)
• TALENs/MegaTALs Market Sales By Geography (USD MN)
• ZFN Market Sales By Geography (USD MN)
• Meganuclease Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Delivery Method (USD MN)
• Ex-vivo Market Sales By Geography (USD MN)
• In-vivo Market Sales By Geography (USD MN)
• Analysis By Application (USD MN)
• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Market Sales By Geography (USD MN)
• Clinical Applications (Diagnostics, Therapy Development) Market Sales By Geography (USD MN)
• Analysis By Mode (USD MN)
• Contract Market Sales By Geography (USD MN)
• In-House Market Sales By Geography (USD MN)
• Analysis By End-use (USD MN)
• Biotechnology and Pharmaceutical Companies Market Sales By Geography (USD MN)
• Academic and Government Research Institutes Market Sales By Geography (USD MN)
• Contract Research Organizations Market Sales By Geography (USD MN)
• Global Genome Editing Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Genome Editing Report
• Market Research Process
• Market Research Methodology
• Global Genome Editing Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Technology
• Market Attractiveness Analysis By Delivery Method
• Market Attractiveness Analysis By Application
• Market Attractiveness Analysis By Mode
• Market Attractiveness Analysis By End-use
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Technology (USD MN)
• CRISPR-Cas9 Market Sales By Geography (USD MN)
• TALENs/MegaTALs Market Sales By Geography (USD MN)
• ZFN Market Sales By Geography (USD MN)
• Meganuclease Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Delivery Method (USD MN)
• Ex-vivo Market Sales By Geography (USD MN)
• In-vivo Market Sales By Geography (USD MN)
• Global Market Analysis By Application (USD MN)
• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Market Sales By Geography (USD MN)
• Clinical Applications (Diagnostics, Therapy Development) Market Sales By Geography (USD MN)
• Global Market Analysis By Mode (USD MN)
• Contract Market Sales By Geography (USD MN)
• In-House Market Sales By Geography (USD MN)
• Global Market Analysis By End-use (USD MN)
• Biotechnology and Pharmaceutical Companies Market Sales By Geography (USD MN)
• Academic and Government Research Institutes Market Sales By Geography (USD MN)
• Contract Research Organizations Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.